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Introduction 
Diarrheal disease is a leading cause of child mortality in many 
low-income countries, accounting for 700 000 deaths annually 
among children under 5 y of age.1 It is also a leading cause of 
hospitalization among children under 5 in low and upper income 
countries.2 Over the past several years, two rotavirus diarrhea 
vaccines have been developed and licensed by the US Food and 
Drug Administration and pre-qualified by the World Health 
Organization.3 This has sparked the first wide-scale introduc- 
tion of a diarrheal vaccine into routine vaccination schedules in 
developed and developing countries. The successful development 
of a third vaccine with a substantially lower cost (ROTAVAC) 
could accelerate introduction into additional low-income set- 
tings, including India.4 The introduction process for rotavirus 
vaccines included substantial attention to documenting the eco- 
nomic value at the national and global levels5. 
Although rotavirus is often the most common cause of mod- 
erate to severe diarrhea in children under 5,6 other diarrheal 
pathogens contribute substantial health and economic burden. 
Vaccines currently exist for other diarrheal infections, including 
cholera and typhoid.7 Additional vaccines against Shigella and 
enterotoxigenic Escherichia coli (ETEC) are also under develop- 
ment. This raises a question of whether there is adequate evidence 
of the economic value of these other vaccines in different set- 
tings. While there is substantial work on the economic value of 
rotavirus vaccines, this may not be directly transferable to other 
anti-diarrheal vaccines. Unlike rotavirus, other enteric pathogens 
(e.g., cholera, typhoid, Shigella and ETEC) tend to be more het- 
erogeneous in their distributions, in part due to their transmis- 
sion through poor water, sanitation and hygiene.6 In addition, 
these other pathogens can affect a much broader age range of 
individuals and not just children under 5 y. 
Assessments of economic value of vaccines typically include 
analyses of the economic benefits themselves (e.g., averted med- 
ical costs or productivity losses), as well as assess whether the 
health benefits of vaccine introduction provided good economic 
value in comparison to the investment cost. The most common 
economic benefits include direct medical costs averted (i.e., 
reduced medications, diagnostics, and services), other direct 
expenses such as travel, and reduced productivity losses (indirect 
costs). Evaluations also assess the economic value of vaccines as 
an investment, in comparison to the health or economic gains. 
Although terminology differs slightly, cost-effectiveness analy- 
ses compare net costs of vaccines to the health gains measured 
as Disability-Adjusted Life Years (DALYs). Cost-utility analyses 
compare net costs to health gains measured as Quality-Adjusted 
Life Years (QALYs). Cost-benefit analyses compare economic 
costs of vaccines to the total monetized value of benefits, either as 
a Benefit-Cost Ratio (BCR) or net benefit. 
In general, assessments of the economic value of rotavirus 
vaccines have focused on the costs associated with acute illness 
and mortality. However there is growing evidence that diarrheal 
illness can have important long-term consequences including 
under-nutrition,8 cognitive function,9 chronic gastrointestinal 
conditions,10 metabolic syndrome,11 and rheumatologic condi- 
tions.12,13 It is unclear the extent to which these outcomes may 
affect the overall economic value of the vaccines. 
Several authors have also argued that traditional economic 
evaluations may underestimate the value of the vaccines, by 
ignoring broader health and social effects. Barnighausen and 
colleagues identify three categories of broader benefits.14 These 
include outcome-related productivity gains behavior-related 
productivity gains, and community externalities. Outcome- 
related productivity gains refer to improved cognitive function 
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may have a disproportional effect on poor 
households and may contribute to struc- 
tural impoverishment and poverty traps 
which can create a macro-economic drag 
on an economy.16,17 
The purpose of this paper is to sys- 
tematically review the evidence of the 
economic value of diarrheal vaccines. 
Our primary questions include whether 
there is evidence of the economic value 
of diarrheal vaccines, and how these ben- 
efits differ by setting, vaccine type, and 
other factors. This includes assessing the 
economic benefits of vaccination, as well 
as the economic value of vaccination as 
an investment (compared with the health 
benefits). We also explore the extent to 
which the literature addresses the poten- 
tial broader economic benefits of diar- 
rheal vaccines. 
Methods 
and educational attainment. Behavior-related productivity gains 
are based on the potential effect of reduced child mortality on 
reduced fertility. This demographic response would presumably 
result in an increased per child investment in health and educa- 
tion, thus increasing human capital. It is also possible that the full 
household economic value of a vaccine may exceed the expected 
cost reduction if they are willing to pay a risk premium to avoid 
worrying about whether their child gets sick. Drummond and 
colleagues refer to this as “utility in anticipation.”15 Others have 
argued that the household costs associated with diarrheal disease 
Eligibility criteria 
A systematic search to locate peer- 
reviewed articles on economic evalua- 
tions of enteric vaccines was conducted 
in two of the major electronic databases 
(PubMed and Web of Science). The 
search was performed in March of 2014 
and the limits of the search were: English 
language and a publication date  rang- 
ing from 2000 to 2014. We followed the 
guidelines set forth by.18 
The articles selected for the final 
review had to be specific to enteric vac- 
cines and economic evaluations. No 
restriction was placed on type of popu- 
lation. Similarly, there were no restric- 
tions in the country or region studied. 
Articles not related to enteric vaccines or 
that were not economic evaluations were 
excluded in the final review. Other exclu- 
sion criteria included articles with incom- 
plete data, articles without original data, 
editorials, meeting abstracts and reviews. 
Search strings 
The search string used in the different databases (modified 
according to each of the search features) was: (“cost-effective- 
ness” OR “economic evaluation” OR “cost of illness” OR “cost 
benefit analysis”) AND (“diarrhea” OR “diarrhoea” OR “rota- 
virus” OR “salmonella” OR “norwalk virus” OR “cholera” OR 
“ETEC” OR “shigella” OR “gastroenteritis” OR “norovirus”) 
AND (“vaccine” OR “vaccination” OR “immunization”) 
Eligibility assessment and study selection 
. Figure 1. Article exclusion and selection flowchart. 
(continued) 
Table 1. Summary of economic evaluations of diarrheal vaccines in low- and middle-income counties, by pathogen. All base case and range values are in 
2014 inflation-adjusted US$ 
Author (Reference) Year Location Vaccine
Target 
population
Type of 
analysis*
Base case Range Units
Abbott et al.45 2012 Ghana Rotavirus Universal child CeA 46 2–72 $/DALY
Atherly et al.46 2009
72 GAVI-eligible 
countries
Rotavirus Universal child CeA 96–515 17–515 $/DALY
Atherly et al.47 2012
72 GAVI-eligible 
countries
Rotavirus Universal child CeA 47 34–260 $/DALY
Bakir et al.48 2013 Turkey Rotavirus Universal child CBA -31,161,329
(-29,371,560)-(- 
32,221,605)
US$ offset with 
vaccine
Berry et al.27 2010 Malawi Rotavirus Universal child CeA 6 6–89 $/DALY
Centenari et al.35 2010 Northeast Brazil Rotavirus Mass campaign CBA
(-10,106)- 
1,428,824
-
US$ offset with 
vaccine
Chang et al.49 2013 Taiwan Rotavirus Universal child CeA CS-95,382 - $/DALY
Chotivitayatarakorn 
et al.50
2010 Thailand Rotavirus Universal child CeA 455 228–933 $/DALY
Clark et al.51 2009 Peru Rotavirus Universal child CeA 779 289–787 $/DALY
Connolly et al.33 2012 egypt Rotavirus
0–72 y after 
vaccination
CBA
6,955,644– 
64,919,348
-
Incremental Net 
Present Value 
(US$)
Constenla et al.52 2008 Brazil Rotavirus Universal child CeA 890 472–890 $/DALY
Constenla et al.36 2009 Mexico Rotavirus Universal child CeA 1,401 373–1,401 $/DALY
Cook et al.53 2008
Kolkata, India; North 
Jakarta, Indonesia; 
Hue, Vietnam; 
Karachi, Pakistan
Typhoid
Adults and children 
(2–15 y old)
CeA 181–4,648 181–4,817 $/DALY
Cook et al.29 2009 Kolkata, India Typhoid
Adults and children 
(2–15 y old)
CeA 181–558 - $/DALY
Cook et al.28 2009 Kolkata, India Cholera Adults and Children CBA 779,032 -
Total Social 
Benefits (US$)
de Blasio et al.54 2014 Kazakhstan Rotavirus Universal child CeA 19,143–25,347 -
US$/Life year 
gained
De la Hoz et al.55 2010 Colombia Rotavirus Universal child CeA 10,779 - $/DALY
de Soarez et al.56 2008 Brazil Rotavirus Universal child CeA 525–875 -
US$/Life Years 
Saved
esposito et al.57 2011 India Rotavirus Universal child CeA 26 CS-239 $/DALY
Fischer et al.58 2005 Vietnam Rotavirus Universal child CeA 122 CS-258 $/DALY
Flem et al.59 2009 Kyrgyzstan Rotavirus Universal child CeA 260 CS-260 $/DALY
Ho et al.60 2008 Hong Kong, China Rotavirus Universal child CeA CS-587,413 CS-651,573 $/DALY
Isakbaeva et al.61 2007 Uzbekistan Rotavirus Universal child CeA 657 126–1,322 $/DALY
Jeuland et al.30 2009 Mozambique Cholera
Children, 
adolescents, and 
mass campaign
CBA 1.3 1.2–6.4
Benefit-Cost 
ratio
Jeuland et al.62 2009
Bangladesh, 
India, Indonesia, 
Mozambique
Cholera All ages CeA 2,150–28,797 1,329–28,797 $/DALY
Jeuland et al.63 2009
Low-income 
countries
Cholera
Children, 
adolescents, and 
mass campaign
CBA 1.1 0.1–9.4
Benefit-Cost 
ratio
Jit et al.64 2011 Armenia Rotavirus Universal child CeA 50–957 50–10,692 $/DALY
Kim et al.21 2008 Hue, Vietnam Cholera All ages wTP 71 -
Average 
willingness to 
pay (US$)
Kim et al.65 2009 Vietnam Rotavirus Universal child CeA 726 - $/DALY
Kim et al.66 2010
72 GAVI-eligible 
countries
Rotavirus Universal child CeA CS-37,112 - $/DALY
Abbreviations: *CeA, Cost-effectiveness analysis; CUA, Cost-utility analysis; CBA, Cost-benefit analysis; wTP, willingness to pay. 
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Table 1. Summary of economic evaluations of diarrheal vaccines in low- and middle-income counties, by pathogen. All base case and range values are in 
2014 inflation-adjusted US$ (continued) 
Author (Reference) Year Location Vaccine
Target 
population
Type of 
analysis*
Base case Range Units
Kim et al.67 2011 Zimbabwe Cholera Mass campaign CeA CS-3,308 - $/DALY
Kim et al.68 2011
72 GAVI-eligible 
countries
Rotavirus Universal child CeA 1,135 CS-37,156 $/DALY
Kotsopoulos et al.34 2013 Ghana and Vietnam Rotavirus Universal child CBA
9,229,830– 
29,705,200
-
Incremental 
Benefit 
(immunization 
tax)
Lauria et al.31 2009
South and Southeast 
Asia
Typhoid Mass campaign CBA 283 -
Median US$/ 
case avoided
Liu et al.69 2012 China Rotavirus Universal child CeA 1,648–8,142 CS-12,471 $/DALY
Muangchana et al.70 2012 Thailand Rotavirus Universal child CeA 148,460–164,784 148,460–172,869 $/DALY
Ortega et al.71 2009
Arab Republic of 
egypt
Rotavirus Universal child CBA 474 - $/DALY
Patel et al.72 2013 Pakistan Rotavirus Universal child CeA 159 - $/DALY
Podewils et al.73 2005 Asia Rotavirus Universal child CeA 150–12,177 CS-21,997 $/DALY
Poulos et al.74 2004 India Typhoid Universal child CBA CS-142 -
US$ / case 
averted
Rheingans et al.75 2009
Low and middle- 
income countries 
grouped by wHO 
regions
Rotavirus Universal child CeA 16–501 CS-55,424 $/DALY
Rheingans et al.37 2012
25 GAVI-eligible 
countries
Rotavirus Universal child CeA 32–158 21–276 $/DALY
Rose et al.76 2009 India Rotavirus Universal child CeA 247 245–247
US$ / Life year 
saved
Sardar et al.22 2013 Zimbabwe Cholera Outbreak CeA 18,990–1,113,945 -
US$ / case 
averted
Schaetti et al.23 2012 Tanzania Cholera Adult CeA 34,778 - $/DALY
Smith et al.77 2011 Bolivia Rotavirus Universal child CeA 162 CS-505 $/DALY
Stack et al.78 2011
72 GAVI-eligible 
countries
Rotavirus Universal child CBA 40,100,449,504 -
US$ saved / case 
averted
Suwantika et al.79 2013 Indonesia Rotavirus Universal child CeA 190–198 160–222 $/QALY
Tate et al.38 2009 Kenya Rotavirus Universal child CeA 33 CS-713 $/DALY
Tate et al.80 2011 Uganda Rotavirus Universal child CeA 5 - $/DALY
Tu et al.81 2012 Vietnam Rotavirus Universal child CeA 771 CS-771 $/QALY
Valencia-Mendoza 
et al.82
2008 Mexico Rotavirus Universal child CeA 5,426 -
US$ / life-year 
saved
van Hoek 
et al.83
2012 Kenya Rotavirus Universal child CeA 155–315 155–320 $/DALY
Verguet et al.39 2013 India and ethiopia Rotavirus Universal child CeA 8,742–17,484 8,742–28,411 Financial risk 
protection 
afforded (US$)
wang et al.84 2009 China Rotavirus Universal child CBA CS All CS US$ saved / case 
averted
whittington et al.85 2012 Developing 
Countries
Cholera Mass campaign CBA 0–2 0–2 Benefit cost ratio
wilopo et al.86 2009 Indonesia Rotavirus Universal child CeA 148 - $/DALY
Abbreviations: *CeA, Cost-effectiveness analysis; CUA, Cost-utility analysis; CBA, Cost-benefit analysis; wTP, willingness to pay. 
To analyze the search results author RDR set the eligibility 
criteria. Following this, authors MPA and JDA identified the 
exclusion criteria to use for both the first and second exclusion. 
Two teams were formed with authors PC and JA as one team and 
authors MPA and JDA on the other to independently review the 
results and apply the selection criteria. Each author performed 
the eligibility assessment in a standardized manner. Each team 
followed an identical search strategy. 
. 
elevance acc 
After removal of duplicates, the titles and abstracts were read 
to ascertain the article r ording to each author’s inter- 
pretation. This step was the first exclusion, which involved the 
removal through a categorization of articles by editorials lan- 
guage, meeting abstract, news articles, not enteric vaccines, opin- 
ion articles, policy briefs, responses and reviews. After the first 
exclusion, teams compared results and settled disagreements on 
inclusion of articles through consensus (Fig. 1). A second exclu- 
sion was performed based on a more rigorous full text exami- 
nation of the articles selected in the first exclusion. The second 
exclusion included articles that did not have complete data, arti- 
cles that were not economic evaluations, articles without original 
data, studies that did not have quantitative or empirical data and 
those records whose full text was not available. 
Data collection and data items 
For the final set of selected articles, a data extraction sheet (see 
Supplemental Material) was developed that was used through- 
out this step. An initial pilot test of the table was performed with 
15 articles, in order to clarify and modify categories. After this 
JC, JDA, JA, and MPA extracted the following information from 
the included articles: Data were extracted on citation, sponsor, 
location, pathogen, population, type of analysis (cost-effective- 
ness, cost-utility, cost-benefit, or other), perspective, types of 
costs included, health outcomes included, base currency, and 
whether distributional effects were considered. The main out- 
comes included summary measures (cost/DALY, cost/QALY, 
benefit-cost ratio), range, key variables influencing results, and 
authors conclusions. All cost measures were recorded in the pub- 
lished currency, and were subsequently converted to 2014 US 
dollars for comparison. For the full variable list, see Appendix 
1 in Supplemental Material. The extraction results were vali- 
dated by having authors JDA, JA and PC manually identify the 
extracted data within the articles and cross checking each entry. 
Disagreements on placement of items or classifications in the 
table were resolved through consensus. 
Results 
A total of 102 articles were included in the final review (Fig. 1). 
The systematic search of PubMed and Web of Science provided 
a total of 652 citations. Following the removal of duplicates, 442 
articles remained. Of these, 313 were discarded after reviewing 
the titles and abstracts because they did not meet the inclusion 
criteria (for example, they were editorials, meeting abstracts, pol- 
icy briefs or review articles). The full text of the remaining 129 
citations was studied in greater detail, after which 24 additional 
articles were removed during the second exclusion. 105 studies 
were retained for review by author RDR, who identified three 
additional articles to be excluded. 
Our search identified a total of 102 eligible studies on the 
economic value of diarrheal vaccines (Tables 1,2, and 3, Fig. 2). 
The most widely studied pathogen was rotavirus, accounting for 
82% (84) of the eligible studies. This was followed by cholera 
with 11% (11) and typhoid with 5% (5). One study consid- 
ered Norovirus19  and Riddle et al.20  considered Campylobacter, 
ETEC, Shigella vaccines and a hypothetical multiplex vaccine in 
deployed soldiers. The studies also covered a wide range of set- 
tings. A total of 45 studies (44%) focused on high-income set- 
tings and 57 (56%) examined low- and middle-income settings. 
Most studies focused on universal access to childhood vacci- 
nation. This was in part a reflection of the high number of stud- 
ies on rotavirus. Other studies considered targeted introduction 
in outbreak settings21-23  or among travelers.20,24-26 
The studies varied in what benefits were included in the 
analysis. The majority of studies (98%) included estimates of 
the direct medical costs averted through vaccination. Sixty-four 
studies (63%) included other direct costs. Productivity losses 
for caregivers or patients were included in 62 studies (61%) and 
were more likely to be included in studies in high-income set- 
tings compared with low-income settings (Fig. 3). A small num- 
ber of studies included the consumer surplus or willingness to pay 
among parents.21,27-32 
We found no studies that included long-term health conse- 
quences of diarrheal disease or the economic value of prevent- 
ing them. However, two studies did estimate the long-term fiscal 
consequences of rotavirus mortality and morbidity in terms of 
labor productivity and tax revenue differences in immunized vs. 
non-immunized cohorts.33,34 We also found no studies that esti- 
mated changes in fertility due to reduced child mortality, nor the 
economic value of such reductions. Only 14 studies considered 
the distributional effects of diarrheal vaccines.21,22,27-33,35-39 
The studies predominantly used one of three summary mea- 
sures: cost-effectiveness ratio (cost/DALY), cost-utility ratio 
(cost/QALY), or benefit cost ratio (BCR). A number of studies 
also included net costs as a secondary summary measure. Studies 
in low-and middle-income settings were more likely to consider 
cost per DALY and those in high-income setting were more likely 
to report cost per QALY or BCR as a summary measure. 
While the studies used a wide range of criteria, the majority 
concluded that the diarrheal vaccine would provide good eco- 
nomic value over a range conditions considered. Most studies 
provided a base case estimate, many emphasized that the actual 
realized economic value would depend on the price of vaccines 
and the cost of delivery. This was particularly true for rotavirus 
vaccines during early stages of introduction and for other diar- 
rheal vaccines that have not fully introduced. 
Discussion 
Substantial evidence exists for the economic value of pre- 
venting rotavirus diarrhea in a wide range of settings. In high- 
income settings, studies emphasized economic value in terms of 
the direct and indirect costs averted, in comparison to the costs 
of vaccination. In low-income settings the authors often empha- 
sized economic value in terms of the health returns (DALYs) to 
the financial investment in vaccination. In middle-income set- 
tings, both types of value were evidenced. The evidence of eco- 
nomic value for rotavirus vaccine introduction appears to have 
been important in justifying investment by national govern- 
ments, international partners, and in some settings households 
Table 2. Distribution of diarrheal pathogens considered in studies of economic value of vaccines, by income setting. All base case and range values are in 
2014 inflation-adjusted US$ (continued) 
Author 
(Reference)
Year Location Vaccine
Target 
population
Type of 
analysis*
Base case Range Units
Atkins et al.87 2012 england and 
wales
Rotavirus Universal child CUA CS-58,820 CS-92,566 $/QALY
Bartsch et al.19 2012 USA Norovirus Mass campaign CBA CS-3,497 - Cost savings 
(US$)
Bilcke et al.88 2009 Belgium Rotavirus Universal child CUA 85,329–109,971 12,661–109,971 $/QALY
Bruijning-Verhagen 
et al.89
2013 Netherlands Rotavirus Universal child 
and adolescents
CUA 3,693–230,128 - $/QALY
Chodick et al.90 2009 Israel Rotavirus Universal child CUA 13,522–37,725 13,522–62,089 $/QALY
Coyle et al.91 2012 Canada Rotavirus Universal child CUA CS-134,360 - $/QALY
Dhont et al.92 2008 Belgium Rotavirus Universal child CBA 12,655,402–21,694,975 - Costs saved 
(US$)
Diez-Domingo et al.93 2010 Spain Rotavirus Universal child CBA 32,189,552–55,600,135 - Costs avoided 
(US$)
Fisman et al.94 2012 Canada Rotavirus Universal child CeA 2,450 2,450–14,597 $/QALY
Giammanco et al.95 2009 Italy Rotavirus Universal child CeA 160 45–499 N/A
Goosens et al.96 2008 Netherlands Rotavirus Universal child CUA 34,004 34,004–54,462 $/QALY
Huet et al.97 2007 France Rotavirus Universal child CBA 136,145,586 72,522,903– 
136,145,586
US$ avoided
Imaz et al.98 2014 Spain Rotavirus Universal child CUA 298,552 298,552–398,233 $/QALY
Jit and edmunds99 2007 United Kingdom 
(wales and 
england)
Rotavirus Universal child CUA 158,033–207,254 - $/QALY
Jit et al.100 2009 Belgium, england 
and wales, 
Finland, France, 
Netherlands
Rotavirus Universal child CUA 25,082–183,935 CS-493,123 $/QALY
Jit et al.64 2011 Belgium, england 
and wales, 
Finland, France, 
Netherlands
Rotavirus Universal child CUA 25,082–183,935 - $/QALY
Kang et al.101 2012 Republic of Korea Rotavirus Universal child CBA 470 - US$ / case 
averted
López-Gigosis et al.24 2009 Spain Cholera Adult travelers CBA 2.2 - N/A
Lorgelly et al.102 2008 UK Rotavirus Universal child CeA 397,701 - US$ / life year 
saved
Lundkvist et al.25 2009 Canada Cholera Travelers CBA CS-102 - US$ saved/ 
person 
vaccinated
Mangen et al.103 2010 Netherlands Rotavirus Universal child CeA 81,935–96,984 - $/DALY
Martin et al.104 2009 UK Rotavirus Universal child CUA 57,846 28,451–140,602 $/QALY
Melliez et al.105 2007 France Rotavirus Universal child CUA 215,346 - $/QALY
Milne and 
Grimwood106
2009 New Zealand Rotavirus Universal child CUA 40,872 40,872–65,398 $/QALY
Newall et al.107 2007 Australia Rotavirus Universal child CUA 57,219–64,465 CS-64,465 $/QALY
Panatto et al.108 2009 Genoa Province, 
Italy
Rotavirus Universal child CUA CS-15,360 - $/QALY
Papadimitropoulos 
et al.26
2004 USA Typhoid Travelers CeA 249–7,450 - US$ / case 
averted
Perez-Rubio et al.109 2011 Castilla y Leon, 
Spain
Rotavirus Universal child CUA 33,292–106,483 - $/QALY
Riddle et al.20 2008 US Military 
personnel
Multiplex Travelers CeA 1,730 950–1,730 US$ / Duty 
days lost
Abbreviations: *CeA, cost-effectiveness analysis; CUA, cost-utility analysis; CBA, cost-benefit analysis; wTP, willingness to pay. 
Table 2. Distribution of diarrheal pathogens considered in studies of economic value of vaccines, by income setting. All base case and range values are in 
2014 inflation-adjusted US$ (continued) 
Author 
(Reference)
Year Location Vaccine
Target 
population
Type of 
analysis*
Base case Range Units
Riddle et al.20 2008 US Military 
personnel
eTeC Travelers CeA 1,505 877–1,505 US$ / Duty 
days lost
Riddle et al.20 2008 US Military 
personnel
Campylobacter Travelers CeA 1,575 851–1,575 US$ / Duty 
days lost
Riddle et al.20 2008 US Military 
personnel
Shigella Travelers CeA 2,356 1,444–2,356 US$ / Duty 
days lost
Rozenbaum et al.110 2011 Netherlands Rotavirus Universal child CUA 11,923–127,939 CS-243,713 $/QALY
Sansom et at.32 2001 USA Rotavirus Universal child wTP 87–163 - willingness-to- 
pay (US$)
Sato et al.111 2011 Japan Rotavirus Universal child CeA+CUA 124,721 11,013–124,721 $/QALY
Shim et al.112 2009 USA Rotavirus Universal child CUA 128,657–236,259 99,300–236,259 $/QALY
Standaert et al.113 2008 France Rotavirus Universal child CUA 69,223 - $/QALY
Standaert et al.114 2013 Belgium Rotavirus Universal child CUA 81,045 81,045–92,204 $/QALY
Syriopoulou et al.115 2011 Greece Rotavirus Universal child CBA 8,433,442 - US$ saved
Tilson et al.116 2011 Ireland Rotavirus Universal child CUA 185,749 CS-185,749 $/QALY
Tu et al.117 2013 Netherlands Rotavirus Universal child CUA 23,352 4,790–23,352 $/QALY
wang et al.118 2010 USA Rotavirus Universal child CBA 12,600 - US$ / 1000 
person-years
weycker et al.119 2009 USA Rotavirus Universal child CeA 94,886,612 77,379,627– 
94,886,612
Net economic 
benefits (US$)
widdowson et al.120 2007 USA Rotavirus Universal child CeA 265,007–632,620 - US$ / life-year 
saved
wu et al.121 2009 Taiwan Rotavirus Universal child CeA 130–190 - $US / case 
averted
Zhou et al.122 2014 USA Rotavirus Universal child CBA 379,082,622– 
689,768,074
- US$ saved
Zlamy 
et al.123
2013 Austria Rotavirus Universal child CBA 10,129–290,420 - US$ saved
Zomer et al.124 2008 Netherlands Rotavirus Universal child CeA 200,350–208,768 - $/DALY
Abbreviations: *CeA, cost-effectiveness analysis; CUA, cost-utility analysis; CBA, cost-benefit analysis; wTP, willingness to pay. 
themselves. In most instances, the case for the economic value 
of rotavirus vaccination did not require estimates of the addi- 
tional economic benefits from long-term health improvements or 
broader societal benefits. 
However there is substantially less evidence of the economic 
value of other diarrheal vaccines. This may be the result of several 
factors. First, there are no licensed vaccines for some of the patho- 
gens or they may have demonstrated effectiveness in a limited 
number of settings. Second, the relatively high and consistent 
attributable fraction from rotavirus among cases of moderate to 
severe diarrhea may also have contributed to the proliferation of 
studies of economic value, many of which use the same model. 
This raises the question of whether the evidence of economic 
value of rotavirus vaccine can be extended to vaccines for other 
enteric pathogens. Several biological factors may contribute to 
the limited ability to extrapolate rotavirus vaccine results to other 
pathogens. First, other leading diarrheal pathogens individu- 
ally account for a smaller attributable fraction than rotavirus. 
Although higher case fatality rates for some (e.g., cholera) may 
offset this, the smaller attributable fraction implies fewer health or 
economic benefits to balance against vaccine costs. Second, other 
leading diarrheal pathogens tend to affect individuals across a 
wider age range, while rotavirus primarily affects children under 
3 y of age. However the implication is that vaccination may need 
to be repeated throughout life for these other vaccines. 
This suggests that informed decision making about the eco- 
nomic value of these other diarrheal vaccines might require a 
more complete accounting of the long-term and broader eco- 
nomic benefits. One element of this would be more complete 
estimates of the long-term health benefits of diarrheal prevention. 
While these connections remain uncertain, there is growing evi- 
dence that the effects of diarrhea infections extend well beyond 
the acute consequences. A number of studies have documented 
the association between enteric infection and under-nutrition 
even in the absence of acute diarrheal illness.8,40 Fischer-Walker 
and colleagues further demonstrated that repeated diarrheal epi- 
sodes can have a long-term negative impact on cognitive func- 
tion,  independent  of  the  effect  mediated  through  nutrition.9 
Table 3. Health and economic benefits of diarrheal vaccines 
Value or benefit Summary Studies reporting
Narrow Benefits
Reduced diarrheal morbidity and 
mortality
episodes and mortality of diarrheal disease; measured as DALYs, 
QALYs, or the monetized value
19-32,35-38,45-92,94-96,98-121,124,125
Averted medical costs from diarrhea
Reduced costs associated with inpatient, outpatient and informal 
medical care
19,20,22-33,35-39,45-47,49-57,59-63,65- 
99,101-112,114-117,119-122,124,125
Direct non-medical costs
Non-medical out of pocket costs to households such as travel; 
including disrupted travel
21,23,24,26,28- 
31,34,35,38,39,50,51,53,55,58,59,61- 
66,69,70,74-76,79,81,83-86,88,89,91- 
93,95-98,100-108,110-113,116,117,119- 
121,123,125
Indirect or productivity costs Lost time from work for caregivers or patients
19,23-25,28,30,33,34,39,50,53- 
56,58,59,61,62,64,69,70,74- 
76,78,79,81,83-86,88-90,92,93,95- 
104,106-112,115-117,119-122,124,125
Broader Benefits
Herd immunity
Indirect protection of non-vaccinated individuals due to reduced 
force of infection
28,31,39,46,65,87,89,100,103,112,114,117
Non-diarrheal health benefits
Benefits from improved nutrition, reduced co-infection, or 
long-term health improvements (e.g., cardiovascular, chronic GI, 
rheumatologic)
None
Adaptive and averting costs
Costs to household, healthcare facilities and public health system to 
avoid infections which could be avoided with vaccination
None
Long-term averted medical costs
Medical costs associated with chronic health conditions resulting 
from diarrhea
None
Long-term productivity
Costs associated with reduced cognitive function due to diarrhea 
and/or associated malnutrition
None
Demographic adaptive response
Reduced child mortality is expected to result in reduced fertility; 
increased per capita investment in health and education
None
Macro-economic effects from 
impoverishment
Reduced macroeconomic costs associated with impoverishment 
due to repeated high medical treatment costs
None
Distributional or equity effects
Value or willingness to pay for benefits that equally or 
disproportionately benefit the poor
21,22,27-33,35-39
Risk premium or utility in 
anticipation
Value of safety or piece of mind associated with reduced risk of 
illness. This separate from the expected value of health or economic 
outcomes.
None
Adapted from14,15 
Porter and colleagues have demonstrated that some diarrheal 
infections are associated with subsequent chronic gastrointestinal 
problems including irritable bowel syndrome, GERD and dys- 
pepsia.10 DeBoer also found an association with metabolic syn- 
drome.11 Lastly, several studies have found an association with 
rheumatologic conditions.12,13 In addition to these long-term con- 
sequences Ashraf and colleagues found that diarrheal disease epi- 
sodes increased the likelihood of subsequent respiratory illness in 
children in Pakistan.41 Associated with each of these conditions, 
there are likely to be direct medical costs, reduced economic pro- 
ductivity and morbidity that could be measured as DALYs. 
Endemic and epidemic diarrheal disease can force households 
to take additional protective steps, incurring costs (referred to 
as averting costs).42 Presumably, effective vaccination could 
reduce these costs. Outbreaks can also result in costs associated 
with social disruption and infection. These measures in health 
facilities and communities have associates costs, may divert 
resources from other investments, and may result in increased 
antibiotic resistance.43 
In low-income settings, repeated diarrheal episodes can result 
in out-of-pocket costs that are high in comparison to household 
income, even though they may be small in relative terms.17 These 
costs can force households to take out expensive loans, sell pro- 
ductive resources, or forgo important investments like food or 
education, resulting in persistent poverty. This suggests that the 
short-term out-of-pocket costs greatly underestimate the long- 
term cost of illness. Few assessments of the economic value of 
vaccines directly estimated these consequences of out-of-pocket 
costs and none included the long-term costs associated with the 
impoverishment they might create. 
Given the heterogeneity of burden from diarrheal pathogens 
such Shigella, cholera, ETEC, and typhoid, it may be increasingly 
important to assess the distributional effects of vaccination and 
economic value of vaccinating higher risk subpopulations. In 
settings where universal vaccination may not be cost-effective, 
target vaccination of high exposure groups may provide greater 
economic value. 
A final potential economic value of diarrheal vaccines is the 
social externality of reduced fertility associated with declining 
child mortality. Although there is no direct evidence that reduc- 
ing child mortality from diarrhea can spur such a response, this is 
a basic tenet of the demographic transition. If diarrheal vaccines 
can catalyze even a modest response in fertility, it could result in 
the refocusing of health and social investments and stimulating 
long-term development. 
An additional opportunity for increasing the economic value 
of diarrheal vaccines is the development of combined vaccines. 
For pathogens with similar distributions, this could reduce the 
delivery costs while increasing the overall reduction in diarrheal 
disease. 
One of the most commonly cited uncertainties in vaccine 
economic value in the reviewed studies was the price of vaccines. 
Economic market theory would suggest that high economic ben- 
efits or value of a given product (in this case a vaccine) would cre- 
ate an upward pressure on price. However the value of diarrheal 
vaccines in a global context is dependent upon maintaining prices 
that are affordable and can be sustained by donors and national 
governments. Global efforts to reduce the price of future diar- 
rheal vaccines can greatly increase their economic value. This may 
be in the form of advanced market commitments that guarantee 
demand in exchange for reduced prices or creative research and 
development initiatives such as the partnership among Bharat 
Biotech, the Government of India’s Department of Biotechnology, 
PATH, and the US National Institutes of Health that resulted in 
the development of the low-cost ROTAVAC vaccine.44 
Limitations 
The current study has several important limitations. First, the 
reviewed studies utilized a wide range of designs and assump- 
tions, making it difficult to directly compare results. Second, the 
studies were conducted across different settings and the thresh- 
old for what represents sufficient economic value varies across 
settings and is subject to interpretation. Third, the majority of 
the studies considered rely on assumptions regarding critical vari- 
ables such as vaccine price, and in some cases efficacy. As a result, 
the conclusions drawn by authors are often dependent upon the 
feasibility of these assumptions. Lastly, most studies capture only 
a fraction of the potential economic value of diarrheal vaccines. 
When the measured value is sufficient to justify introduction this 
may not represent a problem. However, when measured benefits 
are lower the omission of this unmeasured economic value may 
bias decision-making. 
Figure 3. Health and economic benefits considered in evaluations of 
diarrheal vaccines by income setting. 
Figure 2. Distribution of diarrheal pathogens considered in studies of 
economic value of vaccines, by income setting. 
Conclusions 
Our systematic review of the economic value of diarrheal vac- 
cines demonstrates a growing literature on the issue, in response 
to the increased availability of vaccines and the expanded use 
of economic analysis in related decision-making. The reviewed 
studies suggest substantial economic value of rotavirus vaccines 
across a range of settings, although this is dependent in part on 
vaccine costs. A smaller but important literature suggests that 
other diarrheal vaccines could provide economic value for spe- 
cific populations and conditions. Existing studies rely heavily on 
traditional measures of economic value including averted medi- 
cal costs and productivity losses. However less evidence is avail- 
able on the potential value of diarrheal vaccines in preventing 
related non-diarrheal health conditions or in producing broader 
economic benefits. Assessing the full economic value of new or 
underutilized diarrheal vaccines may require better estimates of 
the broader benefits. 
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